LATS2

Across TCGA pan-cancer cohorts, LATS2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LATS2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where LATS2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types LATS2 is over-expressed in tumor, although a few such as LUAD and PDAC show the opposite, repressed pattern.

LUAD, HNSC, and PDAC are the cancer types where LATS2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LATS2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	−0.749	<.001	8	view →
HNSC	All	III,IV	+0.816	.005	6	view →
PDAC	All	All	−0.382	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LATS2–LUAD

Open the LUAD breakdown →